Kansas City Chiefs running back Isiah Pacheco revealed that he bulked up during the 2025 offseason following an ...

(Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced ...

The AD/PD™ Conference is an annual event attracting ... s Diseases and related neurological disorders. About GT-02287 Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical ...

(Nasdaq: GANX) (“Gain”, or the “Company”), a clinical ... oral presentation as well as a poster were presented at the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson ...

Gain’s lead program in Parkinson’s disease has been awarded funding support early in its development from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Fo ...

(Nasdaq: GANX) ("Gain”, or the "Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced ...

AD/PD™ 2025 is being held April 1-5, 2025, in Vienna, Austria. Details of the poster are as follows: Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the ...

(Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced ...

Slides from the oral presentation at AD/PD 2025 will be available on the Company’s website at https://gaintherapeutics.com. Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical ...